{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:22:23Z","timestamp":1768494143029,"version":"3.49.0"},"posted":{"date-parts":[[2021,1,1]]},"group-title":"Microbiology","reference-count":62,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Replication-restricted modified vaccinia virus Ankara (MVA) is a licensed smallpox vaccine and numerous clinical studies investigating recombinant MVAs (rMVAs) as vectors for prevention of other infectious diseases have been completed or are in progress. Two rMVA COVID-19 vaccine trials are at an initial stage, though no animal protection studies have been reported. Here, we characterize rMVAs expressing the S protein of CoV-2. Modifications of full length S individually or in combination included two proline substitutions, mutations of the furin recognition site and deletion of the endoplasmic retrieval signal. Another rMVA in which the receptor binding domain (RBD) flanked by the signal peptide and transmembrane domains of S was also constructed. Each modified S protein was displayed on the surface of rMVA-infected human cells and was recognized by anti-RBD antibody and by soluble hACE2 receptor. Intramuscular injection of mice with the rMVAs induced S-binding and pseudovirus-neutralizing antibodies. Boosting occurred following a second homologous rMVA but was higher with adjuvanted purified RBD protein. Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice. One or two rMVA vaccinations also prevented recovery of infectious CoV-2 from the lungs. A low amount of virus was detected in the nasal turbinates of only one of eight rMVA-vaccinated mice on day 2 and none later. Detection of subgenomic mRNA in turbinates on day 2 only indicated that replication was abortive in immunized animals.<\/jats:p>\n                <jats:sec>\n                  <jats:title>Significance<\/jats:title>\n                  <jats:p>Vaccines are required to control COVID-19 during the pandemic and possibly afterwards. Recombinant nucleic acids, proteins and virus vectors that stimulate immune responses to the CoV-2 S protein have provided protection in experimental animal or human clinical trials, though questions remain regarding their ability to prevent spread and the duration of immunity. The present study focuses on replication-restricted modified vaccinia virus Ankara (MVA), which has been shown to be a safe, immunogenic and stable smallpox vaccine and a promising vaccine vector for other infectious diseases and cancer. In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2020.12.30.424878","type":"posted-content","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T17:15:10Z","timestamp":1609521310000},"source":"Crossref","is-referenced-by-count":8,"title":["MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease"],"prefix":"10.64898","author":[{"given":"Ruikang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Americo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia L.","family":"Earl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noam","family":"Erez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-8564","authenticated-orcid":false,"given":"Bernard","family":"Moss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2021010307200491000_2020.12.30.424878v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"2021010307200491000_2020.12.30.424878v1.2","first-page":"500","article-title":"Human hepatitis B vaccine from recombinant yeast. 1984","volume":"24","year":"1992","journal-title":"Biotechnology"},{"key":"2021010307200491000_2020.12.30.424878v1.3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.4.284"},{"key":"2021010307200491000_2020.12.30.424878v1.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.14.1577"},{"key":"2021010307200491000_2020.12.30.424878v1.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4029"},{"key":"2021010307200491000_2020.12.30.424878v1.6","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.9.4040-4047.2001"},{"key":"2021010307200491000_2020.12.30.424878v1.7","doi-asserted-by":"publisher","DOI":"10.3354\/dao064013"},{"key":"2021010307200491000_2020.12.30.424878v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243"},{"key":"2021010307200491000_2020.12.30.424878v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.06.059"},{"key":"2021010307200491000_2020.12.30.424878v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32137-1"},{"key":"2021010307200491000_2020.12.30.424878v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2622-0"},{"key":"2021010307200491000_2020.12.30.424878v1.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028436"},{"key":"2021010307200491000_2020.12.30.424878v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.026"},{"key":"2021010307200491000_2020.12.30.424878v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y"},{"key":"2021010307200491000_2020.12.30.424878v1.15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice","volume":"28","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2021010307200491000_2020.12.30.424878v1.16","doi-asserted-by":"crossref","unstructured":"J. H. Erasmus et al., An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci Transl Med 12 (2020).","DOI":"10.1126\/scitranslmed.abc9396"},{"key":"2021010307200491000_2020.12.30.424878v1.17","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.30.229120"},{"key":"2021010307200491000_2020.12.30.424878v1.18","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform","volume":"11","year":"2020","journal-title":"Nat Commun"},{"key":"2021010307200491000_2020.12.30.424878v1.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0401939101"},{"key":"2021010307200491000_2020.12.30.424878v1.20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.5.2678-2688.2005"},{"key":"2021010307200491000_2020.12.30.424878v1.21","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00614-15"},{"key":"2021010307200491000_2020.12.30.424878v1.22","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1283"},{"key":"2021010307200491000_2020.12.30.424878v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30248-6"},{"key":"2021010307200491000_2020.12.30.424878v1.24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.23.7415"},{"key":"2021010307200491000_2020.12.30.424878v1.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.16.4927"},{"key":"2021010307200491000_2020.12.30.424878v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/bs.aivir.2016.07.001"},{"key":"2021010307200491000_2020.12.30.424878v1.27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.22.10847"},{"key":"2021010307200491000_2020.12.30.424878v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(94)90341-7"},{"key":"2021010307200491000_2020.12.30.424878v1.29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1707304114"},{"key":"2021010307200491000_2020.12.30.424878v1.30","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"2021010307200491000_2020.12.30.424878v1.31"},{"key":"2021010307200491000_2020.12.30.424878v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)00039-X"},{"key":"2021010307200491000_2020.12.30.424878v1.33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus","volume":"182","year":"2020","journal-title":"Cell"},{"key":"2021010307200491000_2020.12.30.424878v1.34","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1128\/JVI.64.5.2448-2451.1990","article-title":"Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus","volume":"64","year":"1990","journal-title":"J. Virol."},{"key":"2021010307200491000_2020.12.30.424878v1.35","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00687-09"},{"key":"2021010307200491000_2020.12.30.424878v1.36","first-page":"16 17 11","article-title":"Generation of Recombinant Vaccinia Viruses","volume":"117","year":"2017","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"2021010307200491000_2020.12.30.424878v1.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"2021010307200491000_2020.12.30.424878v1.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15562-9"},{"key":"2021010307200491000_2020.12.30.424878v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/334255a0"},{"key":"2021010307200491000_2020.12.30.424878v1.40","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.07.040189.001045"},{"key":"2021010307200491000_2020.12.30.424878v1.41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.12.6166"},{"key":"2021010307200491000_2020.12.30.424878v1.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16505-0"},{"key":"2021010307200491000_2020.12.30.424878v1.43","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02012-06"},{"key":"2021010307200491000_2020.12.30.424878v1.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0778-2"},{"key":"2021010307200491000_2020.12.30.424878v1.45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.165.1.64"},{"key":"2021010307200491000_2020.12.30.424878v1.46","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4049\/jimmunol.140.4.1022","article-title":"IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses","volume":"140","year":"1988","journal-title":"J Immunol"},{"key":"2021010307200491000_2020.12.30.424878v1.47","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2016.65"},{"key":"2021010307200491000_2020.12.30.424878v1.48","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2-Preliminary Report","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"key":"2021010307200491000_2020.12.30.424878v1.49","doi-asserted-by":"publisher","DOI":"10.1126\/science.292.5514.69"},{"key":"2021010307200491000_2020.12.30.424878v1.50","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq105"},{"key":"2021010307200491000_2020.12.30.424878v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30476-X"},{"key":"2021010307200491000_2020.12.30.424878v1.52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejpb.2018.06.001","article-title":"Stability and suitability for storage and distribution of Ad26.ZEBOV\/MVA-BN(R)-Filo heterologous prime-boost Ebola vaccine","volume":"129","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"2021010307200491000_2020.12.30.424878v1.53","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1128\/JVI.70.9.6418-6424.1996","article-title":"Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza","volume":"70","year":"1996","journal-title":"J. Virol."},{"key":"2021010307200491000_2020.12.30.424878v1.54","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00010-3"},{"key":"2021010307200491000_2020.12.30.424878v1.55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.10.6209"},{"key":"2021010307200491000_2020.12.30.424878v1.56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0705191105"},{"key":"2021010307200491000_2020.12.30.424878v1.57","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1283"},{"key":"2021010307200491000_2020.12.30.424878v1.58","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/jmp.12372","article-title":"A simultaneous oral and intramuscular prime\/sublingual boost with a DNA\/Modified Vaccinia Ankara viral vector-based vaccine induces simian immunodeficiency virus-specific systemic and mucosal immune responses in juvenile rhesus macaques","volume":"47","year":"2018","journal-title":"Journal of Medical Primatology"},{"key":"2021010307200491000_2020.12.30.424878v1.59","doi-asserted-by":"crossref","unstructured":"A. T. Jones et al., HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge. Nature Communications 10(2019).","DOI":"10.1038\/s41467-019-08739-4"},{"key":"2021010307200491000_2020.12.30.424878v1.60","doi-asserted-by":"crossref","unstructured":"R. Forster , H. Fleige , G. Sutter , Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung. Frontiers in Immunology 11(2020).","DOI":"10.3389\/fimmu.2020.01959"},{"key":"2021010307200491000_2020.12.30.424878v1.61","doi-asserted-by":"crossref","first-page":"e1008505","DOI":"10.1371\/journal.ppat.1008505","article-title":"Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses","volume":"16","year":"2020","journal-title":"PLoS Pathog"},{"key":"2021010307200491000_2020.12.30.424878v1.62","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.19.10684-10688.2003"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2020.12.30.424878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:12:18Z","timestamp":1768439538000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2020.12.30.424878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":62,"URL":"https:\/\/doi.org\/10.1101\/2020.12.30.424878","relation":{},"subject":[],"published":{"date-parts":[[2021,1,1]]},"subtype":"preprint"}}